Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
6Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Nasus Pharma Ltd. (NSRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
2Distinct source URLs
6High confidence
0.784Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Nasus Pharma Ltd. Suppliers
Ticker
Name
Confidence
Evidence
APTAR
APTAR
92%
as a small pharmaceutical development company, Aptar, a leading global manufacturer of inhalers, is our sole supplier for supply of its intranasal Unit Dose Spray product, or UDS, to be the delivery …
Reciprocal relationship from CGEN graph: d Compugen. Dr. Livnat Savitzky holds a B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D. with distinction in Human Genetics fr…
for the foreseeable future, and we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining ne…
Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from BCLI graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from BCLI g…
Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY g…
ADAPT-PHARMA-INC-TEVA-PHARMACEUTICALS-LTD-PFIZER
ADAPT-PHARMA-INC-TEVA-PHARMACEUTICALS-LTD-PFIZER
62%
cluding use restrictions contained in the product’s approved labeling; ● distribution and use restrictions imposed by the EMA, FDA or other regulatory authority or agreed to by us as part of a mandat…
APTAR-GROUP-INC
APTAR-GROUP-INC
62%
tion of investigations by regulators or other authorities; and ● the inability to successfully commercialize our product candidates, if approved. 24 Further, our business exposes us to an inherent ri…
Reciprocal relationship from PLX graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from PLX graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from PLX grap…
Nasus Pharma Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
NSRX-DEBT-17124
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
NSRX-DEBT
Debt stack $118,000
90%
Market cache reports total debt of $118,000.
Nasus Pharma Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Nasus Pharma Ltd..
Nasus Pharma Ltd. Ownership
Holder
Name
Confidence
Evidence
NSRX-OWNER-UBS-GROUP-AG
UBS Group AG
95%
13F/ownership overlay lists UBS Group AG; shares held 378; value $835; as of 2025-12-31.
NSRX-OWNER-MORGAN-STANLEY
Morgan Stanley
95%
13F/ownership overlay lists Morgan Stanley; shares held 2,000; ownership 0.02%; value $4,420; as of 2025-12-31.
NSRX-OWNER-BALYASNY-ASSET-MANAGEMENT-L-P
Balyasny Asset Management L.P.
90%
13F overlay lists Balyasny Asset Management L.P. as top holder; 9 tracked holders.
